unlikely that patients' priorities regarding the risk of flare versus the risk of infection would have changed. The updated medication list includes medications introduced to treat RA and SpA, including AS and PsA. We have included perioperative management recommendations for the recently introduced JAK-targeted therapies, baricitinib and upadacitinib, in addition to tofacitinib. We have included new management recommendations for the interleukin-17 (IL-17) blocking agent ixekizumab, the